Randomised open-label compatrison study between carperitide and non-carperitide therapy for acute decompensated heart failure

Randomised open-label compatrison study between carperitide and non-carperitide therapy for acute decompensated heart failure - Human Atrial natriuretic peptide for prevention of Nephrotoxicity in Patients with acute decompensated heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001763

Enrollment

200

Registered

2009-03-10

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute decompensated heart failure

Interventions

more than two days administration of carperitide more than two days administration of intra-venous heart failure treatment drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Systolic BP >=100mmHg 2) Pulmonary congestion 3) Symptom with dyspnea 4) 15 ml/min/1.73m2=<eGFR<60 ml/min/1.73m2 5) Age over 20years 6) Within 12 hours of admission 7) Informed consent obtained

Exclusion criteria

Exclusion criteria: 1) eGFR<15ml/min/1.73m or hemodialysis 2) Severe hypotention or cardioganic shock 3) Patients with dehydration 4) Dominant rightventricular heart failure 5) Intubated patients 6) Acute myocardial infarction 7) Patients with cancer 8) Patients with pregnancy 9) Prior enrollment

Design outcomes

Primary

Measure	Time frame
Evaluation of cchangingthe concentration of serum creatinine, estimated GFR and BUN within 7 days after administration of intravenous heart failure agents (carperitide or niterates)	—

Countries

Japan

Contacts

Public ContactShinichi Shirai

Kokura Memorial Hospital Cardiology

kmhptca@kokura-heart.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026